Visfatin is a newly identified protein preferentially produced in visceral adipose tissue.
1,2 Its tissue expression and plasma levels increase in obesity and diabetes mellitus (DM). 2, 3 On the other hand, pathophysiological role of visfatin in hypertension is unclear. We performed a case-control study to investigate any relation between plasma visfatin levels and blood pressure (BP), insulin sensitivity and inflammation in young patients with newly diagnosed and previously untreated hypertension and without confounding factors for insulin resistance (IR) and inflammation such as dyslipidemia, obesity and DM.
Thirty-three male subjects with new onset hypertension (mean age 22.172.5 years, body mass index (BMI) 24.071.8 kg/m 2 ) referred to Department of Internal Medicine, Gulhane School of Medicine in 12 months and 33 healthy men (mean age 21.171.7 years, BMI 23.671.5 kg/m 2 ) as controls were enrolled. The inclusion criteria for patients were: BMI o25 kg/m 2 , fasting blood glucose o100 mg/dl, triglyceride o150 mg/dl, total cholesterol (TC) o200 mg/dl and normal renal, hepatic and cardiac functions. Secondary causes of hypertension were eliminated by medical history, physical examination and laboratory measurements where necessary. BP was measured with an appropriate arm cuff and a mercury column sphygmomanometer after a resting period of at least 5 min. Two measurements within 5 min were averaged as the systolic and diastolic BPs. Patients were considered hypertensive if their BPs on three separate occasions exceeded 140/ 90 mm Hg. All venous blood samples were drawn after an overnight fast. Plasma visfatin levels were determined by enzyme linked immunosorbant assay method (Phoenix Pharmaceuticals, Belmont, CA, USA). Serum high-sensitivity C-reactive protein (hsCRP) was determined by turbidimetric fixed rate method (Olympus AU-2700, Mishima, Japan). Fasting glucose, TC, high-density lipoprotein-cholesterol and triglycerides were measured by enzymatic colorimetric method with Olympus AU 600 auto analyzer using appropriate reagents. Low-density lipoprotein-cholesterol was calculated by the Friedewald's formula. Serum basal insulin level was determined by the coated tube method (DPC, Los Angeles, CA, USA). Homeostasis Model Assessment Model (HOMA) was used to determine the insulin sensitivity index. Results are expressed as mean7s.d. or median (range). Data were evaluated using SPSS 11.0 for Windows (SPSS Inc., Chicago, IL, USA).
The characteristics of the study group and the controls are described in Table 1 . Mean age and BMI were similar in the two groups. Systolic and diastolic BPs were significantly higher in patients (Po0.001, for both). The plasma visfatin levels in the two groups were similar (P ¼ 0.06). In addition, there were no significant differences between the two groups in BMI, lipid profiles, fasting glucose, immunoreactive insulin and hsCRP levels, and HOMA-IR indexes. Plasma visfatin levels did not correlate with the BP, BMI, lipid parameters, glucose, immunoreactive insulin or hsCRP levels as well as HOMA-IR indexes either in patients or controls. The power of the study, calculated according to results, was 0.65, 0.62 and 0.62 for visfatin, hsCRP and HOMA-IR, respectively.
Adipose tissue secretes multiple bioactive molecules collectively referred to as adipokines. These include leptin, adiponectin, visfatin, tumour necrosis factor-a, resistin, angiotensinogen, interleukin-6, plasminogen activity inhibitor-1 and C-reactive protein. Dysregulated production of these adipokines participates in the pathogenesis of obesity-associated disorders such as type 2 diabetes, hyperlipidemia or hypertension. 4 In this study with a highly selected group of people with hypertension, we found no difference in plasma visfatin, as well as no relation of this novel adipokine with BP. At the cellular level, visfatin binds to the insulin receptor through a region different from that of insulin. It was shown to exert insulin-mimetic effects in cultured cells, lower plasma glucose, stimulate glucose uptake in adipocytes and myocytes, and inhibit glucose release from the liver. 1 Increased plasma visfatin has been reported in patients with obesity 2 and type II DM, 3 indicating a regulatory function in insulin sensitivity. Although IR is already associated with increase in BP, at least half of the hypertensive people are not insulin resistant. 5 However, such patients usually have other cardiovascular risk factors related to IR and inflammation, such as obesity, dyslipidemia or DM. Moreover, IR and inflammation may precede the development of hypertension. 6 Ruling out these confounding factors in our study may be the explanation for the similar visfatin levels and HOMA indexes. Lack of any significant difference between the two groups suggests that the effect of IR and inflammation in hypertension probably occurs owing to chronic exposure to associated risk factors for cardiovascular disease.
Although visfatin is highly expressed in visceral fat and circulating levels correlate with obesity, 1 the data regarding its association with the measures of obesity are conflicting. Chen et al. 3 reported a positive correlation between plasma visfatin and waist-to-hip ratio (WHR) but not with BMI. However, no correlation of blood visfatin levels was reported with BMI or WHR in two other investigations. 2, 7 Finally, a recent study on 189 subjects with a wide range of obesity concluded that plasma visfatin levels or visceral visfatin mRNA expression correlated with BMI but not with visceral fat mass or WHR. 8 Therefore, to exclude the confounding effects of obesity on plasma visfatin, we enrolled only the lean people with BMI below 25%, and found no correlation between plasma visfatin and BMI in the whole study population. All these results suggest that alterations in visfatin levels might be regulated by factors other than obesity alone.
Current evidence suggests a role for visfatin in the regulation of inflammatory response. It was recently reported that the main visfatin-secreting cells in the adipose tissue are macrophages, 9 which play a pivotal role in inflammation. Visfatin is also a secretory product of activated leukocytes, and stimulates the expression of several interleukins. 10 In the clinical setting, it was reported to prolong neutrophil survival in sepsis. However, the pathophysiologic role of visfatin in the diseases related to inflammation has not been clarified. In this study, levels of hsCRP, a reliable inflammation marker, were similar in the two groups. We have recently reported in a similar hypertensive group that plasma concentrations of adiponectin, which is another adipokine associated with inflammation, and hsCRP or soluble CD40 levels are not altered at the time of diagnosis. 11, 12 These results might be due to the selection criteria of the participants. However, this kind of study populations can give clearer data regarding the behaviour of adipokines and inflammatory mediators at the initiation of hypertension that is usually complicated in the later course by coronary heart disease, DM, dyslipidemia, etc., which are already accompanied by inflammation. Moreover, even medications can influence the blood levels of these molecules, and thereby interfere with the results.
In conclusion, the results of this preliminary report do not suggest any association of plasma visfatin levels with BP, insulin sensitivity and inflammation in young hypertensive patients, indicating that dysregulation of this adipokine may not be a part of pathogenesis of new onset hypertension. Although a specifically selected group of patients were studied, limited patient number, low study power and use of HOMA equation instead of clamp test in determining IR are the limitations of this study. Moreover, reflection of the results to the general population was not a primary goal. Larger studies on hypertensives with multiple cardiovascular risk factors may help to analyse the independent effects of visfatin on BP, IR or inflammation. What is known about this topic K Visfatin, a newly discovered adipokine, facilitates adipogenesis and has insulin mimetic properties. K The pathophysiological role of visfatin in conditions with insulin resistance and inflammation such as DM or hypertension is largely unknown.
What this study adds K Plasma visfatin levels are not associated with blood pressure, insulin sensitivity and inflammation in young hypertensive patients, indicating that dysregulation of this adipokine may not be a part of pathogenesis of new onset hypertension.
